Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis
Climacteric. 2024 Apr 15:1-10. doi: 10.1080/13697137.2024.2334083. Online ahead of print.ABSTRACTThis systematic review and meta-analysis investigated the efficacy and safety of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. PubMed, Cochrane Library, Embase and Web of Science were searched for randomized controlled trials (RCTs) published from inception to June 2023, comparing fezolinetant to placebo in postmenopausal women suffering from moderate-to-severe VMS. The mean difference and risk ratio were calculated for continuous and binary outcomes, respectively. R so...
Source: Climacteric - April 15, 2024 Category: Geriatrics Authors: Matheus Pedrotti Chavez Eric Pasqualotto Rafael Oliva Morgado Ferreira Alexandre Hohl Francisco Cezar Aquino de Moraes Pedro Henrique Siedschlag Schmidt Anna Lu íza Soares de Oliveira Rodrigues Joao Roberto de Sa Source Type: research
Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis
Climacteric. 2024 Apr 15:1-10. doi: 10.1080/13697137.2024.2334083. Online ahead of print.ABSTRACTThis systematic review and meta-analysis investigated the efficacy and safety of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. PubMed, Cochrane Library, Embase and Web of Science were searched for randomized controlled trials (RCTs) published from inception to June 2023, comparing fezolinetant to placebo in postmenopausal women suffering from moderate-to-severe VMS. The mean difference and risk ratio were calculated for continuous and binary outcomes, respectively. R so...
Source: Climacteric - April 15, 2024 Category: Geriatrics Authors: Matheus Pedrotti Chavez Eric Pasqualotto Rafael Oliva Morgado Ferreira Alexandre Hohl Francisco Cezar Aquino de Moraes Pedro Henrique Siedschlag Schmidt Anna Lu íza Soares de Oliveira Rodrigues Joao Roberto de Sa Source Type: research
Gender-affirming hormone therapy and cardiovascular health in transgender adults
Climacteric. 2024 Apr 10:1-9. doi: 10.1080/13697137.2024.2310518. Online ahead of print.ABSTRACTA growing number of people identify as transgender and gender non-binary in the USA and worldwide. Concomitantly, an increasing number of patients are receiving gender-affirming hormone therapy (GAHT) to achieve gender congruence. GAHT has far-ranging effects on clinical and subclinical markers of cardiovascular risk. Transgender patients also appear to be at higher risk for cardiovascular diseases compared to their cisgender peers and the impact of gender-affirming therapy on cardiovascular health is unclear. Studies on the eff...
Source: Climacteric - April 10, 2024 Category: Geriatrics Authors: Caroline Ong Monique Monita Minghao Liu Source Type: research
Gender-affirming hormone therapy and cardiovascular health in transgender adults
Climacteric. 2024 Apr 10:1-9. doi: 10.1080/13697137.2024.2310518. Online ahead of print.ABSTRACTA growing number of people identify as transgender and gender non-binary in the USA and worldwide. Concomitantly, an increasing number of patients are receiving gender-affirming hormone therapy (GAHT) to achieve gender congruence. GAHT has far-ranging effects on clinical and subclinical markers of cardiovascular risk. Transgender patients also appear to be at higher risk for cardiovascular diseases compared to their cisgender peers and the impact of gender-affirming therapy on cardiovascular health is unclear. Studies on the eff...
Source: Climacteric - April 10, 2024 Category: Geriatrics Authors: Caroline Ong Monique Monita Minghao Liu Source Type: research
Gender-affirming hormone therapy and cardiovascular health in transgender adults
Climacteric. 2024 Apr 10:1-9. doi: 10.1080/13697137.2024.2310518. Online ahead of print.ABSTRACTA growing number of people identify as transgender and gender non-binary in the USA and worldwide. Concomitantly, an increasing number of patients are receiving gender-affirming hormone therapy (GAHT) to achieve gender congruence. GAHT has far-ranging effects on clinical and subclinical markers of cardiovascular risk. Transgender patients also appear to be at higher risk for cardiovascular diseases compared to their cisgender peers and the impact of gender-affirming therapy on cardiovascular health is unclear. Studies on the eff...
Source: Climacteric - April 10, 2024 Category: Geriatrics Authors: Caroline Ong Monique Monita Minghao Liu Source Type: research
Gender-affirming hormone therapy and cardiovascular health in transgender adults
Climacteric. 2024 Apr 10:1-9. doi: 10.1080/13697137.2024.2310518. Online ahead of print.ABSTRACTA growing number of people identify as transgender and gender non-binary in the USA and worldwide. Concomitantly, an increasing number of patients are receiving gender-affirming hormone therapy (GAHT) to achieve gender congruence. GAHT has far-ranging effects on clinical and subclinical markers of cardiovascular risk. Transgender patients also appear to be at higher risk for cardiovascular diseases compared to their cisgender peers and the impact of gender-affirming therapy on cardiovascular health is unclear. Studies on the eff...
Source: Climacteric - April 10, 2024 Category: Geriatrics Authors: Caroline Ong Monique Monita Minghao Liu Source Type: research
Gender-affirming hormone therapy and cardiovascular health in transgender adults
Climacteric. 2024 Apr 10:1-9. doi: 10.1080/13697137.2024.2310518. Online ahead of print.ABSTRACTA growing number of people identify as transgender and gender non-binary in the USA and worldwide. Concomitantly, an increasing number of patients are receiving gender-affirming hormone therapy (GAHT) to achieve gender congruence. GAHT has far-ranging effects on clinical and subclinical markers of cardiovascular risk. Transgender patients also appear to be at higher risk for cardiovascular diseases compared to their cisgender peers and the impact of gender-affirming therapy on cardiovascular health is unclear. Studies on the eff...
Source: Climacteric - April 10, 2024 Category: Geriatrics Authors: Caroline Ong Monique Monita Minghao Liu Source Type: research
The rs2018736 fibulin-5 polymorphism as a determinant for pelvic organ prolapse: a case-control study
CONCLUSION: The rs2018736-CC genotype of the fibulin-5 gene has a protective role against POP.PMID:38533754 | DOI:10.1080/13697137.2024.2327988 (Source: Climacteric)
Source: Climacteric - March 27, 2024 Category: Geriatrics Authors: Juliana B Teixeira Maria A T Bortolini Rebecca S P Silva Nilce C Batista Carolina L Costa E Silva Kristina Allen-Brady Rodrigo A Castro Source Type: research
The rs2018736 fibulin-5 polymorphism as a determinant for pelvic organ prolapse: a case-control study
CONCLUSION: The rs2018736-CC genotype of the fibulin-5 gene has a protective role against POP.PMID:38533754 | DOI:10.1080/13697137.2024.2327988 (Source: Climacteric)
Source: Climacteric - March 27, 2024 Category: Geriatrics Authors: Juliana B Teixeira Maria A T Bortolini Rebecca S P Silva Nilce C Batista Carolina L Costa E Silva Kristina Allen-Brady Rodrigo A Castro Source Type: research
The rs2018736 fibulin-5 polymorphism as a determinant for pelvic organ prolapse: a case-control study
CONCLUSION: The rs2018736-CC genotype of the fibulin-5 gene has a protective role against POP.PMID:38533754 | DOI:10.1080/13697137.2024.2327988 (Source: Climacteric)
Source: Climacteric - March 27, 2024 Category: Geriatrics Authors: Juliana B Teixeira Maria A T Bortolini Rebecca S P Silva Nilce C Batista Carolina L Costa E Silva Kristina Allen-Brady Rodrigo A Castro Source Type: research
The rs2018736 fibulin-5 polymorphism as a determinant for pelvic organ prolapse: a case-control study
CONCLUSION: The rs2018736-CC genotype of the fibulin-5 gene has a protective role against POP.PMID:38533754 | DOI:10.1080/13697137.2024.2327988 (Source: Climacteric)
Source: Climacteric - March 27, 2024 Category: Geriatrics Authors: Juliana B Teixeira Maria A T Bortolini Rebecca S P Silva Nilce C Batista Carolina L Costa E Silva Kristina Allen-Brady Rodrigo A Castro Source Type: research
The rs2018736 fibulin-5 polymorphism as a determinant for pelvic organ prolapse: a case-control study
CONCLUSION: The rs2018736-CC genotype of the fibulin-5 gene has a protective role against POP.PMID:38533754 | DOI:10.1080/13697137.2024.2327988 (Source: Climacteric)
Source: Climacteric - March 27, 2024 Category: Geriatrics Authors: Juliana B Teixeira Maria A T Bortolini Rebecca S P Silva Nilce C Batista Carolina L Costa E Silva Kristina Allen-Brady Rodrigo A Castro Source Type: research
The rs2018736 fibulin-5 polymorphism as a determinant for pelvic organ prolapse: a case-control study
CONCLUSION: The rs2018736-CC genotype of the fibulin-5 gene has a protective role against POP.PMID:38533754 | DOI:10.1080/13697137.2024.2327988 (Source: Climacteric)
Source: Climacteric - March 27, 2024 Category: Geriatrics Authors: Juliana B Teixeira Maria A T Bortolini Rebecca S P Silva Nilce C Batista Carolina L Costa E Silva Kristina Allen-Brady Rodrigo A Castro Source Type: research
The rs2018736 fibulin-5 polymorphism as a determinant for pelvic organ prolapse: a case-control study
CONCLUSION: The rs2018736-CC genotype of the fibulin-5 gene has a protective role against POP.PMID:38533754 | DOI:10.1080/13697137.2024.2327988 (Source: Climacteric)
Source: Climacteric - March 27, 2024 Category: Geriatrics Authors: Juliana B Teixeira Maria A T Bortolini Rebecca S P Silva Nilce C Batista Carolina L Costa E Silva Kristina Allen-Brady Rodrigo A Castro Source Type: research
The rs2018736 fibulin-5 polymorphism as a determinant for pelvic organ prolapse: a case-control study
CONCLUSION: The rs2018736-CC genotype of the fibulin-5 gene has a protective role against POP.PMID:38533754 | DOI:10.1080/13697137.2024.2327988 (Source: Climacteric)
Source: Climacteric - March 27, 2024 Category: Geriatrics Authors: Juliana B Teixeira Maria A T Bortolini Rebecca S P Silva Nilce C Batista Carolina L Costa E Silva Kristina Allen-Brady Rodrigo A Castro Source Type: research
